Erectile Dysfunction Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Global Erectile Dysfunction Treatment Market is Segmented By Product (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, Vitaros, and Other Products), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The value is provided (in USD million) for the above segments.

Erectile Dysfunction Drugs Market Size

Single User License


Team License


Corporate License


Book before:
Erectile Dysfunction Drugs Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 3.80 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Erectile Dysfunction Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License


Team License


Corporate License


Book before:

Erectile Dysfunction Drugs Market Analysis

The Erectile Dysfunction Drugs Market is expected to register a CAGR of 3.8% over the forecast period.

The COVID-19 pandemic positively impacted the market owing to the underlying disease caused by the adverse effects of COVID-19 leading to the rising prevalence of erectile dysfunction. According to an article published by WebMed, in April 2021, COVID-19 increases the risk of developing erectile dysfunction (ED) by nearly six times. The estimated risk of developing ED was 5.66 times higher in men with a history of COVID-19. Its prevalence in the male COVID-19 group was estimated to be 31.8%. Access to the delivery of elective and non-emergency medical treatment was hampered by COVID-19, particularly during times of significant SARS-CoV-2 community transmission. During the COVID-19 outbreak, numerous elective operations for benign urological disorders like ED were postponed. Additionally, a significant trend toward management providing largely virtual care for issues related to men's sexual health has been seen, with procedures only being offered for emergencies and urgent cancer situations. According to an article published by ScienceDirect, in June 2021, there were 4.4% of video visits of patients for ED in 2020 as compared to 4.5% of office visits in 2019. The article stated that the outpatient population for ED treatment was unaffected by the use of telemedicine. Thus, people opting for telemedicine for the treatment of ED increased substantially. However, currently, as there is better access to erectile dysfunction drugs as compared to the initial pandemic times due to the lockdown, the market is expected to gain its growth pace over the coming 3-4 years.

Factors driving the erectile dysfunction (ED) drugs market include the adoption of a sedentary lifestyle and associated stress, the rising geriatric population, and the comorbidity between erectile dysfunction and heart disease and diabetes. A sedentary lifestyle, alcoholism, and smoking greatly increase the risk of erectile dysfunction. According to the study published by BMC Endocrine Disorders, in July 2021, alcohol consumption, poor glycemic control, age, and diabetes duration were all found to be predictors of erectile dysfunction. Erectile dysfunction was found to be prevalent in 72.2% of people globally, in 2021. Thus, old age, diabetes, alcohol consumption, and poor glycemic control were found to have a significance on erectile dysfunction, thereby driving the market growth.

Erectile dysfunction is the most common risk factor in men, and its incidence increases with age. Aging and older men frequently have comorbidities, like diabetes mellitus, chronic obstructive pulmonary disease, hypertension, cardiovascular diseases, and many others; likewise, they concurrently refer to a clinician for impairments in sexual function, mostly for erectile dysfunction (ED). For instance, according to the article published by the NIH, in June 2021, sexual dysfunctions are common in people with diabetes and may arise from a variety of vascular, neurologic, and hormonal derangements. Furthermore, the rise in the number of ED cases is often correlated with the high growth of obesity, diabetes, and cardiovascular disorders. Hypertension is additionally another major illness linked to male erectile dysfunction. As reported by the WHO in 2021, the prevalence of hypertension has grown at a substantial rate and an estimated 1.28 billion adults aged 30 to 79 years have been affected by hypertension, with the majority (two-thirds) living in low- and middle-income countries. Hence, the increase in the prevalence of erectile dysfunction is likely to create a demand for drugs to treat the dysfunction, which is boosting the market growth.

However, the reluctance of patients to seek treatment and poor patient adherence to ED drugs are the factors restraining the market growth.

Erectile Dysfunction Drugs Market Trends

This section covers the major market trends shaping the Erectile Dysfunction Drugs Market according to our research experts:

The Viagra (sildenafil citrate) Segment is Expected to Dominate the Market

Erectile dysfunction is treated with the drug sildenafil. It helps men get an erection by increasing blood flow to the penis. Viagra is the most common drug used as first-line therapy in the treatment of erectile dysfunction. Viagra is also used to treat pulmonary arterial hypertension, which causes ED. According to an article published by Hims & Hers Health, Inc., in June 2021, more than 95% of erectile dysfunctional males who used sildenafil said they were satisfied with the way it affected their erections.

Furthermore, according to an article published by Inverse, in February 2020, Sildenafil is a popular option for men seeking to treat erectile dysfunction as it helps erections last for three to five hours after taking the medication. Sildenafil is sold under the trade name Viagra, which is highly well-known and earns its parent company, Pfizer, an estimated USD 1.8 billion annually.

Therefore, the above-mentioned factors are expected to drive segmental growth in the market during the forecast period.

Erectile Dysfunction Drugs Market : Physical Cause of Erectile Dysfunction (in Percentage), United States, 2021

North America is Expected to Dominate the Market over the Forecast Period

North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED, and the presence of better healthcare infrastructure. According to the September 2022 published article by MSD Manuals, in the United States, about 50% of men 40 to 70 years of age are somewhat affected by ED, and the percentage increases with aging. Furthermore, as per an article published by the National Institute of Diabetes and Digestive and Kidney Diseases, in 2021, ED affected approximately 30 million men in the United States. Besides, the country has the highest rate of self-reported ED which is expected to drive market growth over the forecast period.

Moreover, studies and product launches for the effective treatment of ED are also contributing to the market growth. For instance, in January 2022, Petros Pharmaceuticals, Inc., initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil). Furthermore, in September 2022, Lupin Limited launched Sildenafil for oral suspension, 10 mg/mL, having received approval from the US FDA. Such advancements are driving the market.

Erectile Dysfunction Drugs Market- Growth Rate by Region

Erectile Dysfunction Drugs Industry Overview

The erectile dysfunction drugs market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known including Apricus Biosciences Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline PLC, Metuchen Pharmaceuticals LLC, S.K. Chemicals Co. Ltd, Teva Pharmaceutical Industries Ltd, and VIVUS Inc., among others.

Erectile Dysfunction Drugs Market Leaders

  1. Pfizer Inc.

  2. GlaxoSmithKline plc.

  3. Bayer AG

  4. Eli Lilly and Company

  5. Lupin

*Disclaimer: Major Players sorted in no particular order

Erectile Dysfunction Drugs Market Concentration
Need More Details on Market Players and Competitors?
Download Sample

Erectile Dysfunction Drugs Market News

  • In September 2021, iX Biopharma, through its wholly-owned subsidiary, signed an agreement with CRPCG for the licensing, supply, and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.
  • In September 2021, Almus announced the launch of Almus Erectile Dysfunction Relief 50mg Film-Coated Tablets to the UK pharmaceutical market.

Erectile Dysfunction Drugs Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Defination

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress

      2. 4.2.2 Rising Geriatric Population

      3. 4.2.3 Comorbidity between Erectile Dysfunction and Heart Diseases and Diabetes

    3. 4.3 Market Restraints

      1. 4.3.1 Reluctance of Patients to Seek Treatment

      2. 4.3.2 Poor Patient Adherence to ED Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size in USD million)

    1. 5.1 Product

      1. 5.1.1 Viagra (sildenafil citrate)

      2. 5.1.2 Cialis (Tadalafil)

      3. 5.1.3 Levitra/Staxyn (vardenafil)

      4. 5.1.4 Stendra/Spedra (avanafil)

      5. 5.1.5 Zydena (udenafil)

      6. 5.1.6 Vitaros (Alprostadil Cream)

      7. 5.1.7 Other Products

    2. 5.2 Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Apricus Biosciences Inc.

      2. 6.1.2 Bayer AG

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Petros Pharmaceutical

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 S.K. Chemicals Co. Ltd

      8. 6.1.8 Teva Pharmaceutical Industries Ltd

      9. 6.1.9 VIVUS Inc.

      10. 6.1.10 Lupin Limited

      11. 6.1.11 Glenmark Pharmaceuticals Limited

      12. 6.1.12 Cipla Ltd

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Erectile Dysfunction Drugs Industry Segmentation

As per the scope of this report, erectile dysfunction is a very common condition, and it can be defined as the inability to maintain an erection sufficient for sexual intercourse. The Erectile Dysfunction Drugs Market is segmented By Product (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, Vitaros, and Other Products), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Vitaros (Alprostadil Cream)
Other Products
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America
Need A Different Region Or Segment?
Customize Now

Erectile Dysfunction Drugs Market Research FAQs

The Erectile Dysfunction Drugs Market is projected to register a CAGR of 3.80% during the forecast period (2024-2029)

Pfizer Inc., GlaxoSmithKline plc., Bayer AG, Eli Lilly and Company and Lupin are the major companies operating in the Erectile Dysfunction Drugs Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Erectile Dysfunction Drugs Market.

The report covers the Erectile Dysfunction Drugs Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Erectile Dysfunction Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Erectile Dysfunction (ED) Drugs Industry Report

Statistics for the 2024 Erectile Dysfunction (ED) Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Erectile Dysfunction (ED) Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Erectile Dysfunction Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)